Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Accumulated Expenses (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Accumulated Expenses for 6 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 258.91% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.7 million, a 258.91% increase, with the full-year FY2025 number at $44.7 million, up 258.91% from a year prior.
  • Accumulated Expenses was $44.7 million for Q4 2025 at GeneDx Holdings, up from $26.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $44.7 million in Q4 2025 to a low of $7.3 million in Q2 2024.
  • A 5-year average of $19.7 million and a median of $18.4 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 59.04% in 2024, then skyrocketed 285.52% in 2025.
  • GeneDx Holdings' Accumulated Expenses stood at $20.1 million in 2021, then increased by 1.02% to $20.3 million in 2022, then plummeted by 40.05% to $12.2 million in 2023, then increased by 2.17% to $12.4 million in 2024, then surged by 258.91% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Accumulated Expenses are $44.7 million (Q4 2025), $26.4 million (Q3 2025), and $28.1 million (Q2 2025).